MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting ...
Cytosine and adenosine base editors (CBEs and ABEs) are integral to molecular breeding, enable precise modification of single-nucleotide polymorphisms (SNPs) in plants, which are crucial for agronomic ...
(MEMPHIS, Tenn. – July 03, 2023) Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia. These two common life-threatening anemias afflict ...
Researchers have found that a new base-editing gene therapy can help treat a rare neurodevelopmental disorder called Snijders Blok–Campeau syndrome caused by mutations in the CHD3 gene. A specialized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results